AMGN.NEO Amgen CDR (CAD Hedged)
- Market cap
- -
- P/E
- 40.3x
- P/B
- 19.97x
- ROE
- 71.8%
- Dividend yield
- 2.56%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AMGN.NEO undervalued?
Graham numberThe Graham number of Amgen CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amgen CDR (CAD Hedged) fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (71.8%), above 20%.
ROA 1/1
Return on assets (8.8%) is above the industry median (7.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (87.9%) is below the industry median (90.5%).
Revenue Growth 2/2
Revenue grew 11.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (443.7%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 4.6x against interest expense, below 5x.
PE vs Market 0/1
PE (40.3x) is above the market median (20.3x).
PE vs Industry 0/1
PE (40.3x) is above the industry median (25.0x).
PBV 0/1
Price to book (20.0x) is above the industry median (8.1x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 805.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.6%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 66.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Amgen CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amgen CDR (CAD Hedged)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…
Full company profileAmgen CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amgen CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 26.3B | 28.2B | 33.4B | 36.8B | 37.3B |
| Gross Profit | 19.9B | 19.7B | 20.6B | 24.7B | 26.2B |
| Operating Income | 9.57B | 7.90B | 7.26B | 9.08B | 12.4B |
| EBITDA | 12.2B | 14.8B | 13.4B | 16.9B | 16.8B |
| Net Income | 6.55B | 6.72B | 4.09B | 7.71B | 8.39B |
| EPS | 12 | 13 | 7.62 | 14 | 16 |
| Balance Sheet | |||||
| Total Assets | 65.1B | 97.2B | 91.8B | 90.6B | 95.6B |
| Total Liabilities | 61.5B | 90.9B | 86.0B | 81.9B | 84.0B |
| Shareholders' Equity | 3.66B | 6.23B | 5.88B | 8.66B | 11.7B |
| Cash & Short-term Investments | 7.63B | 10.9B | 12.0B | 9.13B | 14.0B |
| Cash Flow | |||||
| Operating Cash Flow | 9.72B | 8.47B | 11.5B | 9.96B | 12.4B |
| Capital Expenditure | 936M | 1.11B | 1.10B | 1.86B | 2.45B |
| Free Cash Flow | 8.79B | 7.36B | 10.4B | 8.10B | 9.93B |
| Ratios | |||||
| ROE | 179.0% | 107.8% | 69.6% | 89.1% | 71.8% |
| ROA | 10.1% | 6.9% | 4.5% | 8.5% | 8.8% |
| Net Profit Margin | 24.9% | 23.8% | 12.2% | 21.0% | 22.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Amgen CDR (CAD Hedged) dividends
- Dividend yield
- 2.56%
- Forward dividend
- -
- Payout ratio
- 66.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.12B | 9.51 | 66.5% |
| 2024 | USD 4.83B | 9.00 | 118.1% |
| 2023 | USD 4.56B | 8.51 | 67.8% |
| 2022 | USD 4.20B | 7.86 | 64.0% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Amgen CDR (CAD Hedged)
Ownership data of Amgen CDR (CAD Hedged) is not available yet.
Amgen CDR (CAD Hedged) company profile
- Company name
- Amgen CDR (CAD Hedged)
- Ticker
- AMGN.NEO
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 28,000
- Fiscal year end
- December
- Address
- One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
- Phone
- 805 447 1000
- Website
- amgen.com
About Amgen CDR (CAD Hedged)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen CDR (CAD Hedged) management
10- Mr. Robert A. BradwayChairman, CEO & President · born 1963
- Mr. Peter H. GriffithExecutive VP & CFO · born 1959
- Dr. David M. Reese M.D.Executive VP & CTO · born 1963
- Mr. Murdo GordonExecutive Vice President of Global Commercial Operations · born 1967
- Dr. James E. Bradner M.D.Executive Vice President of Research & Development · born 1972
- Mr. Esteban SantosExecutive Vice President of Operations · born 1968
- Mr. Matthew C. BuschChief Accounting Officer & VP of Finance · born 1975
- Mr. Scott SkellengerSenior VP & Chief Information Officer
- Dr. Howard Y. Chang M.D., Ph.D.Senior VP of Global Research & Chief Scientific Officer
- Justin G. ClaeysVice President of Investor Relations